首页> 美国卫生研究院文献>Pediatric Health Medicine and Therapeutics >Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease
【2h】

Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease

机译:taliglucerase alfa在小儿1型Gaucher病患者中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gaucher disease (GD) is a heritable storage disorder caused by functional defects of the lysosomal acid β-glucosidase and the accumulation of glucosylceramide within macrophages, resulting in multiple organ dysfunction. There are three commercially available enzyme replacement therapy (ERT) products for the treatment of GD type 1 (GD1): imiglucerase, velaglucerase alfa, and taliglucerase alfa. Imiglucerase and velaglucerase alfa are produced in different mammalian cell systems; imiglucerase requires postproduction deglycosylation to expose terminal α-mannose residues, which are required for mannose receptor-mediated uptake by target macrophages. These steps are critical to the success of ERT for the treatment of visceral and hematologic manifestations of GD. Taliglucerase alfa is the first US Food and Drug Administration-approved plant-cell-expressed recombinant human protein, using carrot root cell cultures. Furthermore, it does not require postproduction glycosidic modifications. It is indicated for treatment of adults with GD1 in the US, Israel, Australia, Canada, Chile, Brazil, and other countries, and it is additionally approved for the treatment of pediatric patients in the US, Australia, and Canada and for the treatment of hematologic manifestations in pediatric patients with Type 3 GD in Canada and other countries. Our review focuses on the role of taliglucerase alfa in the pediatric population. A literature search through PubMed (from 1995 up till November 2016) of English language articles was performed with the following terms: Gaucher disease, lysosomal storage disease, taliglucerase. Secondary and tertiary references were obtained by reviewing related articles as well as the website . It has been demonstrated that taliglucerase alfa is efficacious, with a well-established safety profile in pediatric, ERT-naïve patients with symptomatic GD1, as well as for those patients previously treated with imiglucerase.
机译:高雪氏病(GD)是一种可遗传的贮积病,由溶酶体酸β-葡萄糖苷酶的功能缺陷和巨噬细胞内葡萄糖基神经酰胺的积累引起,导致多器官功能障碍。存在三种用于治疗1型GD(GD1)的市售酶替代疗法(ERT)产品:伊米苷酶,维拉苷酶α和taligluceraseα。异葡糖苷酶和维拉苷酶α在不同的哺乳动物细胞系统中产生。伊米苷酶需要生产后去糖基化以暴露末端α-甘露糖残基,这是目标巨噬细胞对甘露糖受体介导的摄取所必需的。这些步骤对于ERT治疗GD内脏和血液学表现的成功至关重要。 Taliglucerase alfa是美国食品和药物管理局批准的第一个使用胡萝卜根细胞培养物的植物细胞表达重组人蛋白质。此外,它不需要后期生产的糖苷修饰。它被指定在美国,以色列,澳大利亚,加拿大,智利,巴西和其他国家用于治疗患有GD1的成人,并在美国,澳大利亚和加拿大被批准用于治疗儿科患者以及用于治疗加拿大和其他国家/地区的小儿3型GD患者的血液学表现我们的审查集中在他莱克葡糖酶α在儿科人群中的作用。从PubMed(从1995年到2016年11月)对英语文章进行了文献检索,搜索内容包括以下术语:高雪氏病,溶酶体贮积病,滑石粉酶。通过阅读相关文章和网站获得二级和三级参考。已经证明,在儿童中,无ERT症状的有症状GD1的儿童以及以前接受过伊米苷酶治疗的患者中,塔利克苷酶α是有效的,并具有公认的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号